We showed that LCK inhibitors such as dasatinib, bosutinib, nintedanib, and WH-4-023 can induce cell death in GC-resistant T-ALL cells, and remarkably, cotreatment with dexamethasone is able to reverse GC resistance, even at therapeutic drug concentrations. Here, LCK is linked to acute lymphoblastic leukemia.